Cara Therapeutics, Inc. (NASDAQ:CARA) a clinical-stage biopharmaceutical company, is expected to report second quarter earnings results, after market close, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.67 per share.
Looking ahead, the full year loss are expected at $ 2.61 per share on the revenues of $ 21.87 million.
Previous Quarter Performance
Cara Therapeutics, Inc. recorded loss for the first quarter of $ 0.62 per share, from the revenue of $ 8.09 million. According to street consensus, CARA was expected to report 1Q20 loss of $ 0.62 per share from revenue of $ 4.76 million. The bottom line results street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 3.33 million or 69.96 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Cara Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of CARA was $ 16.95, representing a 90.88 % increase from the 52 week low of $ 8.88 and a 36.45 % decrease over the 52 week high of $ 26.67.
The company has a market capital of $ 793.19 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CARA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Cara Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.caratherapeutics.com
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the bodys peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus.
